NEUROONE MEDICAL TECHNOLOGIES Corp
NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) develops thin-film electrode and ablation technologies for neurological diagnosis and treatment, including epilepsy, Parkinson’s disease and pain conditions. Its commercialized products include Evo cortical and sEEG electrodes for temporary recording, monitoring… From the company’s description.
Over the twelve months to Jun 30, 2026, NEUROONE MEDICAL TECHNOLOGIES Corp reported revenue of $9.47M, up 42.8% from a year earlier, and a net loss of $7.45M. Its operating margin was −83.4%, and operations used $7.05M in cash. In fiscal 2025, it reported revenue of $9.10M, up 163.5% from fiscal 2024, and a net loss of $3.61M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What NEUROONE MEDICAL TECHNOLOGIES Corp does
In the company’s own words
NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) develops thin-film electrode and ablation technologies for neurological diagnosis and treatment, including epilepsy, Parkinson’s disease and pain conditions. Its commercialized products include Evo cortical and sEEG electrodes for temporary recording, monitoring and stimulation of the brain, and OneRF systems for brain and trigeminal nerve ablation. The company also has drug-delivery, spinal cord stimulation and basivertebral nerve ablation technologies in development. Its products serve physicians and healthcare providers, with Zimmer holding exclusive global distribution rights for the Evo cortical and sEEG products and OneRF Brain Ablation System. NeuroOne reports a single business focused on medical technology rather than separate reportable segments. In fiscal 2025, it received approximately $9.1 million in product revenue from its products distributed by Zimmer. The OneRF TN Ablation System entered a limited market release in December 2025, after the fiscal year ended.
Company details
- Sector
- Health Care
- Industry (SIC)
- Surgical & Medical Instruments
- Headquarters
- EDEN PRAIRIE, MN
- Fiscal year end
- September
- CIK
- 1500198
- SIC
- 3841
Financial performance, year by year
Fiscal 2011–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns NEUROONE MEDICAL TECHNOLOGIES Corp — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · NEUROONE MEDICAL TECHNOLOGIES Corp’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do NEUROONE MEDICAL TECHNOLOGIES Corp and its peers compare on margins and cash generation over ten years?”
- “Where did five years of NEUROONE MEDICAL TECHNOLOGIES Corp's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in NEUROONE MEDICAL TECHNOLOGIES Corp's last four quarterly filings that the numbers alone won't show?”